LON:COG Cambridge Cognition (COG) Share Price, News & Analysis → Tech GIANT’s Plans to Revolutionize Crypto… (From Crypto 101 Media) (Ad) Free COG Stock Alerts GBX 45 -1.40 (-3.02%) (As of 05/24/2024 ET) Add Compare Share Share Today's Range 44▼ 4550-Day Range 43.20▼ 5752-Week Range 43▼ 104Volume6,634 shsAverage Volume61,360 shsMarket Capitalization£15.82 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsHeadlinesStock AnalysisChartCompetitorsHeadlines Ad Crypto 101 MediaTech GIANT’s Plans to Revolutionize Crypto…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. About Cambridge Cognition Stock (LON:COG)Cambridge Cognition Holdings Plc, a neuroscience technology company, develops and markets near-patient cognitive testing techniques in the United States, United Kingdom, the European Union, and internationally. The company offers CANTAB digital cognitive assessment platform for drug development by enabling pharmaceutical companies to take new therapeutics from preclinical consultancy to pivotal studies and approval, as well as supports sponsors to enhance recruitment, develop safe and effective treatments, and enhance research and development efficiency. It also provides CANTAB Connect Research, a proprietary platform that provides insights into behaviours, underlying brain circuits, and measurement of digital cognitive biomarkers; CANTAB Mobile, a touchscreen assessment of memory, mood, and functional status to detect the earliest signs of clinically relevant memory problems; CANTAB Insight to assess cognitive health; and CANTAB BrainHealth for assessing workplace wellbeing. In addition, the company offers electronic questionnaires and scales, a digital bespoke questionnaire; NeuroVocalix, a voice analysis platform to analyze voice to assess neurological change; cognition kit, a high frequency testing kit to detect changes over time and day-to-day cognition with short regular tests using patients' own devices. Cambridge Cognition Holdings Plc was incorporated in 2012 and is based in Cambridge, the United Kingdom.Read More COG Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart COG Stock News HeadlinesMay 24 at 6:56 AM | nytimes.comA Jaw-Dropping Question is Answered a Decade LaterMay 24 at 6:56 AM | msn.comSome birds may use ‘mental time travel,’ study findsMay 24 at 4:54 AM | americanbankingnews.comCambridge Cognition (LON:COG) Shares Cross Below Two Hundred Day Moving Average of $52.33May 24 at 12:11 AM | msn.comHundreds of Harvard students walk out of commencement ceremony in protest of Israel-Hamas warMay 23 at 7:10 PM | msn.comThese birds may be capable of ‘mental time travel’ much like humans use to retrieve memoriesMay 22, 2024 | finance.yahoo.comSinaptica Therapeutics Selected for StartUp Health’s Alzheimer’s MoonshotMay 20, 2024 | nytimes.comThe Painstaking Quest to Portray a Tortured WarriorMay 17, 2024 | msn.comOpinion: We could have retired years ago. Here’s why we’re still workingMay 14, 2024 | msn.comMore than 20,000 people join search for new dementia treatmentsMay 6, 2024 | thetimes.co.ukWhat to eat to boost your brain: it’s all about balanceMay 5, 2024 | yahoo.comWhat is dementia? Types, symptoms, causes and treatmentMay 3, 2024 | forbes.comSam Altman Answers The Burning Questions About AI: Bias, Privacy, Etc.May 2, 2024 | finance.yahoo.comAmolyt Pharma Granted FDA Fast Track Designation for Eneboparatide for the Treatment of HypoparathyroidismMay 2, 2024 | dailymail.co.ukFrom stress to success. Stay calm and focused with this revolutionary 'chill pill'May 1, 2024 | msn.comFeathers, cognition and global consumerism in colonial AmazoniaMay 1, 2024 | lse.co.ukEARNINGS: Anexo revenue up; Maintel hails "confident start" to 2024April 30, 2024 | msn.comThe emotional impact of debt: Strategies for effective copingApril 25, 2024 | msn.comUniversity of Cambridge researchers use AI to find highly potent Parkinson’s drug candidates in a tenth of the usual timeApril 24, 2024 | msn.comBiogen reports sales of Alzheimer’s drug exceeded expectationsApril 23, 2024 | lse.co.ukCambridge Cognition partly-owned spin-off gets GBP1.5 million fundingApril 21, 2024 | thetimes.co.ukCambridge in free-speech row over researcher’s ‘race realism’ blogApril 17, 2024 | msn.comSage Therapeutics stock plunges 23 percent after Parkinson’s drug fails studyApril 17, 2024 | bizjournals.comSage halts trials in Parkinson’s after drug fails to show benefitApril 17, 2024 | msn.comAI speeds up drug design for Parkinson's by ten-foldApril 17, 2024 | msn.comA window into Alzheimer's and early detection - how regular eye exams could helpSee More Headlines Company Calendar Last Earnings9/22/2020Today5/26/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Health Information Services Sub-IndustryN/A Current SymbolLON:COG CUSIPN/A CIKN/A Webwww.cambridgecognition.com Phone44 1223 810 700FaxN/AEmployees80Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.10) Trailing P/E RatioN/A Forward P/E Ratio454.55 P/E GrowthN/ANet Income£-3,740,000.00 Net Margins-29.25% Pretax MarginN/A Return on Equity-630.55% Return on Assets-13.31% Debt Debt-to-Equity Ratio18.95 Current Ratio0.45 Quick Ratio0.96 Sales & Book Value Annual Sales£12.77 million Price / Sales1.24 Cash FlowGBX 10.45 per share Price / Cash Flow4.31 Book ValueGBX 3 per share Price / Book15.00Miscellaneous Outstanding Shares35,150,000Free FloatN/AMarket Cap£15.82 million OptionableNot Optionable Beta0.80 Key ExecutivesDr. Matthew William Stork (Age 56)CEO & Director Comp: $342kMr. Stephen Daniel Symonds (Age 48)CFO & Executive Director Comp: $203.31kMr. John HammondCo-FounderMr. Nick TaptiklisHead of Technology StrategyMs. Francesca Cormack Ph.D.Chief Scientist & Member of Scientific Advisory BoardMr. Simon MerrittMarketing and Communications DirectorDr. Lisa Elizabeth Nolan Ph.D. (Age 62)Vice President Business Development Ms. Nicky AckerleyGlobal HR DirectorProf. Trevor Robbins CBEFBPsS, FMedSci, FRS, Ph.D., Senior ConsultantProf. Barbara Sahakian FBPsSFMedSci, Senior ConsultantMore ExecutivesKey CompetitorsRenalytixLON:RENXInduction Healthcare GroupLON:INHCFeedbackLON:FDBKIQ-AILON:IQAITrellus HealthLON:TRLSView All Competitors COG Stock Analysis - Frequently Asked Questions How have COG shares performed in 2024? Cambridge Cognition's stock was trading at GBX 51.50 at the beginning of the year. Since then, COG stock has decreased by 12.6% and is now trading at GBX 45. View the best growth stocks for 2024 here. How were Cambridge Cognition's earnings last quarter? Cambridge Cognition Holdings Plc (LON:COG) announced its quarterly earnings results on Tuesday, September, 22nd. The company reported ($1.50) EPS for the quarter. Cambridge Cognition had a negative trailing twelve-month return on equity of 630.55% and a negative net margin of 29.25%. What other stocks do shareholders of Cambridge Cognition own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cambridge Cognition investors own include Interserve (IRV), Alio Gold Inc. (ALO.TO) (ALO), Concepta PLC (CPT.L) (CPT), European Metals (EMH), IntelGenx Technologies (IGXT), Oxford Biomedica (OXB), Syneos Health (SYNH), Travelers Companies (TRV), Amryt Pharma (AMYT) and AltynGold (ALTN). How do I buy shares of Cambridge Cognition? Shares of COG stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:COG) was last updated on 5/26/2024 by MarketBeat.com Staff From Our Partners[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 MediaWARNING about the death of the U.S. dollar…Colonial MetalsMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlace$1,500 to $9,400 in one month? (A.I. Trade List)Prosper Trading AcademyClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsBill Gates is all about this tiny $2 stockTimothy SykesNew Options need New Trading StrategiesNetpicksWrite this ticker symbol down…StocksToTrade Adding Choose a watchlist: Watchlist My Default Watchlist Adding Cambridge Cognition Holdings Plc You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.